Premium
Post Transplant Lymphoproliferative Disorder risk factors in children: Analysis of a 23‐year single‐institutional experience
Author(s) -
Bosse Raphael C.,
Franke Aaron J.,
Paul Skelton William,
Woody Lindsey E.,
Bishnoi Rohit,
Wang Yu,
BhaduriMcIntosh Sumita,
Rajderkar Dhanashree,
Shih Renata,
Dang Nam H.,
Slayton William B.
Publication year - 2020
Publication title -
pediatric transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 69
eISSN - 1399-3046
pISSN - 1397-3142
DOI - 10.1111/petr.13747
Subject(s) - medicine , univariate analysis , multivariate analysis , malignancy , cohort , univariate , transplantation , serology , pediatrics , multivariate statistics , immunology , antibody , statistics , mathematics
PTLD is the most frequent malignancy following SOT in children and the second most common SOT complication in adults. However, factors determining outcomes in children are poorly understood due to its relative rarity. Methods This study was performed at the University of Florida. Univariate and multivariate analyses were used to identify prognostic factors in pediatric patients diagnosed with PTLD. Results We reviewed records of 54 pediatric (younger than 18 years old at diagnosis) patients diagnosed with PTLD from 1994 to 2017. The median follow‐up was 28.8 months. The estimated 5‐year survival rate was 87.6% (95% CI 74.3‐94.2%). Univariate analysis showed that organ transplanted (specifically heart transplant), poor response to initial treatment, allograft rejection, and low Karnofsky score were statistically significant for negative prognostic factors in determining survival. Multivariate analysis determined progression in response to initial treatment and presence of allograft rejection as statistically significant prognostic factors affecting overall survival. We found no statistically significant impact of EBV serological status on PTLD prognosis. Conclusions Disease progression and allograft rejection were strong negative prognostic indicators in our study cohort. Close attention to graft status and development of therapies that protect the graft from rejection while bolstering anti‐EBV immunity will be essential to further improving PTLD outcomes in children.